Soluble receptor for advanced glycation end products (sRAGE) and asthma: Mendelian randomisation study
- 5 March 2021
- journal article
- letter
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5), 1100-1103
- https://doi.org/10.1111/pai.13478
Abstract
No abstract availableKeywords
Funding Information
- NIH Clinical Center (R01 AI‐148338)
- National Institutes of Health (R01 AI‐134940)
This publication has 11 references indexed in Scilit:
- Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individualsNature Metabolism, 2020
- The axis of the receptor for advanced glycation endproducts in asthma and allergic airway diseaseAllergy, 2020
- Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK BiobankJournal of Allergy and Clinical Immunology, 2019
- Shared genetics of asthma and mental health disorders: a large-scale genome-wide cross-trait analysisEuropean Respiratory Journal, 2019
- Reading Mendelian randomisation studies: a guide, glossary, and checklist for cliniciansBMJ, 2018
- A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseasesNature Genetics, 2018
- Decreased soluble RAGE in neutrophilic asthma is correlated with disease severity and RAGE G82S variantsMolecular Medicine Reports, 2017
- sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cellsScientific Reports, 2017
- Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis through IL-33 and accumulation of group 2 innate lymphoid cellsJournal of Allergy and Clinical Immunology, 2015
- UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old AgePLoS Medicine, 2015